Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based ...

In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year ...

Johnson & Johnson JNJ announced a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotech developing ...

The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation. There are signs that some of the structural problems that have dogged the ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

Zentalis Pharmaceuticals, Inc. focuses on developing azenosertib with a pivotal Denali Phase 2 trial underway. Learn more ...

In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...

West Pharmaceutical Services, Inc. ( WST) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM EST ...

THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire / ...

DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire ...